BNP Paribas Financial Markets’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-94
| Closed | -$470 | – | 4259 |
|
|
2024
Q1 | $470 | Sell |
94
-3
| -3% | -$19 | ﹤0.01% | 3902 |
|
|
2023
Q4 | $652 | Hold |
97
| – | – | ﹤0.01% | 3879 |
|
|
2023
Q3 | $892 | Sell |
97
-3,005
| -97% | -$60.4K | ﹤0.01% | 3751 |
|
|
2023
Q2 | $65.5K | Buy |
3,102
+912
| +42% | +$28.1K | ﹤0.01% | 3394 |
|
|
2023
Q1 | $58.9K | Buy |
2,190
+1,959
| +848% | +$91.1K | ﹤0.01% | 3411 |
|
|
2022
Q4 | $8.17K | Sell |
231
-201
| -47% | -$24.1K | ﹤0.01% | 3629 |
|
|
2022
Q3 | $97.5K | Buy |
432
+122
| +39% | +$30K | ﹤0.01% | 3786 |
|
|
2022
Q2 | $58.6K | Buy |
310
+209
| +207% | +$42.1K | ﹤0.01% | 3519 |
|
|
2022
Q1 | $25K | Sell |
101
-443
| -81% | -$70K | ﹤0.01% | 3693 |
|
|
2021
Q4 | $84.7K | Buy |
544
+317
| +140% | +$61.3K | ﹤0.01% | 3643 |
|
|
2021
Q3 | $45.5K | Buy |
227
+104
| +85% | +$24.7K | ﹤0.01% | 3536 |
|
|
2021
Q2 | $31.5K | Sell |
123
-16
| -12% | -$3.99K | ﹤0.01% | 3413 |
|
|
2021
Q1 | $37K | Sell |
139
-71
| -34% | -$22.4K | ﹤0.01% | 3677 |
|
|
2020
Q4 | $77.5K | Sell |
210
-10
| -5% | -$2.87K | ﹤0.01% | 3340 |
|
|
2020
Q3 | $53.8K | Buy |
220
+178
| +424% | +$55.4K | ﹤0.01% | 3432 |
|
|
2020
Q2 | $12K | Sell |
42
-198
| -83% | -$58.4K | ﹤0.01% | 3628 |
|
|
2020
Q1 | $49K | Buy |
240
+150
| +167% | +$47.8K | ﹤0.01% | 3546 |
|
|
2019
Q4 | $40.2K | Sell |
90
-9
| -9% | -$3.19K | ﹤0.01% | 3755 |
|
|
2019
Q3 | $30.3K | Buy |
+99
| New | +$32.2K | ﹤0.01% | 3752 |
|
|
2018
Q2 | – | Sell |
-2
| Closed | -$621 | – | 4501 |
|
|
2018
Q1 | $621 | Hold |
2
| – | – | ﹤0.01% | 4113 |
|
|
2017
Q4 | $879 | Hold |
2
| – | – | ﹤0.01% | 4104 |
|
|
2017
Q3 | $693 | Hold |
2
| – | – | ﹤0.01% | 4103 |
|
|
2017
Q2 | $498 | Buy |
+2
| New | +$454 | ﹤0.01% | 4138 |
|
|
2017
Q1 | – | Sell |
-2
| Closed | -$689 | – | 3996 |
|
|
2016
Q4 | $664 | Sell |
2
-7
| -78% | -$2.56K | ﹤0.01% | 4039 |
|
|
2016
Q3 | $3.78K | Buy |
9
+4
| +80% | +$2.04K | ﹤0.01% | 3423 |
|
|
2016
Q2 | $2.71K | Buy |
+5
| New | +$3.04K | ﹤0.01% | 3427 |
|
Other funds holding EIGR
BNP Paribas Financial Markets's EIGR Position: Q2 2024 in Review
BNP Paribas Financial Markets sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 94 shares — an estimated $470 sold.
BNP Paribas Financial Markets first reported a position in EIGR in Q2 2016 and held it in 26 quarters. The position peaked at $97.5K in Q3 2022. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- BNP Paribas Financial Markets reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- BNP Paribas Financial Markets sold 94 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $470.
- BNP Paribas Financial Markets first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2016 and held it in 26 quarters.
- BNP Paribas Financial Markets's Eiger BioPharmaceuticals, Inc. position peaked at $97.5K in Q3 2022.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2024, filed 13 Aug 2024.